CJC-1295 DAC vs GHRP-6.

CJC-1295 with DAC (also written DAC:GRF, CJC-1295 DAC) is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH). It is built on the bioactive N-terminal GHRH(1-29) fragment with several amino-acid substitutions, plus a "Drug Affinity Complex" (DAC): a maleimidopropionyl group that lets the peptide bind covalently to circulating albumin after injection. It was developed in the mid-2000s by ConjuChem Biotechnologies as an investigational drug; it is not an approved medicine and today circulates mainly as a research/gray-market peptide.

GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. First described by endocrinologist Cyril Y. Bowers and colleagues in the mid-1980s, it was the prototype of the growth hormone secretagogue (GHS) class and the chemical ancestor of later peptides such as GHRP-2, hexarelin, and ipamorelin. It is not a hormone replacement; rather, it provokes the body's own pituitary to release growth hormone.

Like native GHRH, CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs and stimulates synthesis and pulsatile release of growth hormone (GH), which in turn drives hepatic and peripheral IGF-1 production. Two engineering features extend its action: amino-acid substitutions in the GHRH(1-29) backbone resist cleavage by dipeptidyl-peptidase-4 (DPP-4), and the DAC maleimide group forms a covalent bond with cysteine-34 of serum albumin, shielding the peptide from renal filtration and proteolysis so it persists in plasma for days rather than minutes. Because it amplifies the body's own GH axis rather than supplying exogenous GH, secretion remains somewhat pulsatile and subject to negative feedback (e.g., somatostatin).

GHRP-6 is a synthetic agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), the G-protein-coupled receptor cloned in 1996 whose endogenous ligand, ghrelin, was identified in 1999. Receptor activation drives phospholipase C signaling, raising inositol trisphosphate and diacylglycerol, mobilizing intracellular calcium and activating protein kinase C, which triggers GH release from somatotrophs. This pathway is distinct from and synergistic with GHRH (which signals through cAMP/PKA), and GHRP-6 also acts on the hypothalamus to amplify GHRH tone and suppress somatostatin. Separately, GHRP-6 binds the scavenger receptor CD36, which is implicated in its proposed cytoprotective and anti-ischemic effects independent of GH release. It also stimulates appetite (via NPY/AgRP arcuate neurons) and can transiently raise cortisol and prolactin.

Human evidence comes mainly from early-phase ConjuChem trials in healthy adults. Teichman et al. (JCEM, 2006) reported that single subcutaneous doses produced dose-dependent, sustained elevations of GH and IGF-1, with IGF-1 remaining above baseline for several days and repeated weekly/biweekly dosing maintaining elevated IGF-1. Ionescu and Frohman (JCEM, 2006) showed that despite continuous GHRH-receptor stimulation, GH secretion remained pulsatile in healthy men. Preclinical support includes Alba et al. (Am J Physiol Endocrinol Metab, 2006), where once-daily CJC-1295 normalized growth in GHRH-knockout mice, and Sackmann-Sala et al. (Growth Horm IGF Res, 2009), which characterized GH/IGF-1-axis-driven serum protein changes. Crucially, there are no published controlled trials demonstrating clinical outcomes (body composition, strength, fat loss, anti-aging, or healing) in humans; the human data establish a pharmacodynamic GH/IGF-1 effect, not proven therapeutic benefit, and the program was discontinued without an approved indication.

In humans, the best-established data are pharmacological/diagnostic: GHRP-6 reliably and synergistically stimulates GH secretion (especially combined with GHRH) and was studied as a GH-provocative agent and probe of the somatotropic axis in the 1990s. Beyond GH provocation, the much-publicized cytoprotective, cardioprotective, and wound/scar-reducing claims rest almost entirely on preclinical work: rodent myocardial infarction and reperfusion models, a rat/rabbit wound and hypertrophic-scar study (Plastic Surgery International, 2016, animal-only), and doxorubicin-cardiotoxicity models. A Clinical Science (2006) paper proposed GHRP-6 for prevention of multiple organ failure, but this remained largely conceptual/preclinical. There are no large, completed, peer-reviewed randomized human trials demonstrating clinical benefit for cardioprotection, healing, or body composition; the human-versus-animal gap here is wide and should not be glossed over.

In the short early-phase human studies, the most consistently noted effects were injection-site reactions and transient flushing; sustained IGF-1 elevation also raises theoretical concerns common to GH-axis stimulation, such as fluid retention, joint discomfort, carpal-tunnel-type symptoms, and reduced insulin sensitivity. Long-term human safety is essentially uncharacterized: no large or long-duration controlled trials were completed, and chronically elevated GH/IGF-1 is a biologically plausible (though unproven for this compound) concern for promoting growth of existing neoplasms. Real-world risk is compounded by the fact that material sold as "CJC-1295 DAC" is unregulated and may vary in purity, identity, or sterility. No dosing or administration guidance is provided here.

Documented effects in human GH-testing studies include marked stimulation of appetite and transient, usually modest, increases in cortisol and prolactin alongside the intended GH rise, reflecting limited receptor selectivity compared with newer agents like ipamorelin. Because GHS-R1a agonism raises GH and downstream IGF-1, theoretical concerns include fluid retention, insulin resistance/altered glucose handling, and the general caution that sustained GH/IGF-1 elevation could promote growth of existing tumors; these long-term risks are not well characterized for GHRP-6 specifically. There are no robust long-term human safety data, no established safety in pregnancy, and product purity/identity is a major real-world hazard since material sold for "research" is unregulated. No dosing or administration guidance is provided here.

CJC-1295 (with or without DAC) is not approved by the FDA or any major regulator for any use; clinical development was discontinued and it is treated as an unapproved/investigational substance, with U.S. authorities also flagging it as unsuitable for pharmacy compounding. It is prohibited in sport at all times by the World Anti-Doping Agency as a GH-releasing factor under Category S2 of the Prohibited List.

GHRP-6 is not approved by the FDA (or other major regulators) for any therapeutic indication and is an investigational/research-use-only compound. As a growth hormone secretagogue, it falls under substances prohibited in sport at all times by the World Anti-Doping Agency (WADA).